开立医疗2025年三季报显示，前三季度公司主营收入14.59亿元，同比上升4.37%；归母净利润3351.11 万元，同比下降69.25%；扣非净利润2399.1万元，同比下降72.14%；其中2025年第三季度，公司单季度 主营收入4.95亿元，同比上升28.42%；单季度归母净利润-1351.92万元，同比上升78.05%；单季度扣非 净利润-1588.57万元，同比上升76.92%；负债率24.22%，投资收益207.82万元，财务费用-3830.36万 元，毛利率60.36%。开立医疗（300633）主营业务：医疗诊断及治疗设备的自主研发、生产与销售。 该股最近90天内共有10家机构给出评级，买入评级8家，增持评级2家；过去90天内机构目标均价为 39.71。 证券之星消息，截至2026年1月5日收盘，开立医疗(300633)报收于27.6元，上涨4.47%，换手率1.62%， 成交量7.03万手，成交额1.92亿元。 1月5日的资金流向数据方面，主力资金净流入1235.31万元，占总成交额6.44%，游资资金净流出 1338.34万元，占总成交额6.97%，散户资金净流入103.03万元，占总成交额 ...

Investment Rating - The industry investment rating is "Outperform the Market," indicating an expected performance that exceeds the market by more than 5% over the next six months [29]. Core Insights - The report highlights that the national government will continue to support the renewal of medical equipment in 2026, which is expected to drive demand in the medical device sector. The focus is on high-end equipment and companies with significant performance improvements and international expansion, such as Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical [3]. - The report emphasizes the optimization of application conditions and review processes for equipment renewal projects, aiming to lower investment thresholds and enhance support for small and medium-sized enterprises [3]. - The ongoing policy for equipment renewal is anticipated to sustain a favorable bidding environment for medical devices, with a gradual improvement in performance as inventory clears [3]. Summary by Sections Industry Overview - The report discusses the government's announcement on December 30, 2025, regarding large-scale equipment renewal and the inclusion of various sectors, including healthcare, in the support framework for 2026 [3]. - It outlines the measures to improve the application process for equipment renewal, including stricter requirements for equipment depreciation and minimum usage periods [3]. Investment Opportunities - The report suggests focusing on companies that are expected to show significant performance improvements and have a leading international presence in the medical device sector [3]. - Specific companies recommended for investment include Mindray Medical, United Imaging, Aohua Endoscopy, and Kaili Medical, which are well-positioned to benefit from the anticipated demand for high-end medical equipment [3]. Market Performance - The medical sector has experienced a decline, with a reported drop of 2.06% in the last week, ranking 25th among 28 industries [8][18]. - The report notes that the medical device market is under pressure in the short term due to policy impacts, but improvements are expected as companies innovate and expand internationally [5].

Core Viewpoint - The company, Shenzhen Kaili Biomedical Technology Co., Ltd., has undergone significant governance changes, including the cancellation of its supervisory board and amendments to its articles of association, which were approved during its recent shareholder meeting [2][4]. Group 1: Stock Performance - As of December 31, 2025, the stock price of Kaili Medical closed at 26.42 yuan, down 0.49% from the previous week [1]. - The stock reached a high of 26.59 yuan and a low of 25.92 yuan during the week [1]. - The company's current total market capitalization is 11.432 billion yuan, ranking 26th out of 127 in the medical device sector and 1709th out of 5181 in the A-share market [1]. Group 2: Corporate Governance Changes - The second extraordinary general meeting of shareholders was held on December 30, 2025, where the cancellation of the supervisory board and amendments to the company's governance structure were approved [2][4]. - The meeting was deemed legal and effective, with 55.3717% of the total voting rights represented by attending shareholders [2][4]. - The proposals to cancel the supervisory board and amend the articles of association received over two-thirds approval, while other proposals received a majority [2]. Group 3: Employee Representation - The company held a representative assembly on December 30, 2025, electing Feng Naizhang as the employee representative director for the fourth board of directors [3]. - Feng Naizhang, previously a non-employee representative director, meets the qualifications set forth in the Company Law and the company's articles of association [3]. - The composition of the board and its specialized committees remains unchanged, with the number of concurrent executives and employee representative directors not exceeding half of the total board members [3].

Core Viewpoint - The financial performance of Kaili Medical (300633) shows mixed results, with a slight increase in revenue but a significant decline in net profit, indicating potential challenges ahead for the company [2]. Financial Performance - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year [2]. - The net profit attributable to shareholders was 33.51 million yuan, a decrease of 69.25% year-on-year [2]. - The net profit after deducting non-recurring items was 23.99 million yuan, down 72.14% year-on-year [2]. - In Q3 2025, the company achieved a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year [2]. - The single-quarter net profit attributable to shareholders was -13.52 million yuan, an increase of 78.05% year-on-year [2]. - The single-quarter net profit after deducting non-recurring items was -15.89 million yuan, an increase of 76.92% year-on-year [2]. - The company's debt ratio stands at 24.22%, with investment income of 2.08 million yuan and financial expenses of -38.30 million yuan [2]. - The gross profit margin is reported at 60.36% [2]. Market Activity - As of December 31, 2025, Kaili Medical's stock closed at 26.42 yuan, up 0.84%, with a turnover rate of 0.92% and a trading volume of 40,000 hands, amounting to a transaction value of 105 million yuan [1]. - On December 31, the net inflow of main funds was 15.99 million yuan, accounting for 15.25% of the total transaction value, while retail funds saw a net outflow of 5.25 million yuan, representing 5.01% of the total transaction value [1]. Analyst Ratings - In the last 90 days, 11 institutions have provided ratings for Kaili Medical, with 9 buy ratings and 2 hold ratings [2]. - The average target price set by institutions over the past 90 days is 3.971 billion yuan [2].

Group 1 - The core viewpoint of the articles highlights the significant interest from brokerages in A-share listed companies, with over 2800 companies receiving brokerage research in 2025, indicating that more than half of the market's listed companies have been under brokerage attention [1][2] - The mechanical equipment, electronics, and pharmaceutical biotechnology sectors are identified as the most favored by brokerages, with over 290 companies in each sector receiving research attention [1][2] - The mechanical equipment sector is particularly noted for investment opportunities in the humanoid robot industry chain, while the electronics sector is advised to focus on new technologies and demands driven by the AI innovation cycle [3][4] Group 2 - Crystal Optoelectronics, a company in the electronics sector, has been the most favored by brokerages, receiving 175 research visits, and is part of a sector that has seen a significant price increase of nearly 42% in 2025 [1][2] - The electronics sector has over 320 companies receiving brokerage research, with notable companies like Huaqin Technology and Luxshare Precision receiving more than 140 research visits each [2] - The pharmaceutical biotechnology sector has 296 companies under brokerage research, with a cumulative increase of only 12.44% in 2025, indicating a relative underperformance compared to other sectors [3][4] Group 3 - Investment opportunities in the humanoid robot sector are expected to grow, with a focus on companies entering the Tesla supply chain and those involved in core supply chain and standardization [3] - The electronics sector is anticipated to benefit from the AI-driven demand for high-performance storage and semiconductor testing equipment, suggesting a favorable outlook for related companies [4] - The pharmaceutical sector is expected to continue focusing on innovative drug companies, supported by favorable policies and increasing international market presence, which will attract more investor attention [4]

证券日报网讯 12月30日，开立医疗发布公告称，公司2025年第二次临时股东大会审议通过《关于取消 监事会、修订并办理工商变更登记的议案》等多项议案。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Kaili Medical (300633) as of December 30, 2025, showing a slight decline in stock price and mixed capital flow [1][2]. - As of December 30, 2025, Kaili Medical's stock closed at 26.2 yuan, down 0.49%, with a turnover rate of 0.8% and a trading volume of 34,600 hands, resulting in a transaction amount of 90.73 million yuan [1]. - The capital flow data indicates a net inflow of 9.66 million yuan from main funds, accounting for 10.65% of the total transaction amount, while retail investors experienced a net outflow of 5.95% [1]. Group 2 - For the first three quarters of 2025, Kaili Medical reported a main revenue of 1.459 billion yuan, an increase of 4.37% year-on-year, but a significant decline in net profit by 69.25% to 33.51 million yuan [2]. - The third quarter of 2025 saw a single-quarter main revenue of 495 million yuan, up 28.42% year-on-year, but a net loss of 13.52 million yuan, reflecting a 78.05% increase in losses compared to the previous year [2]. - The company has a debt ratio of 24.22%, with an investment income of 2.08 million yuan and financial expenses of -38.30 million yuan, while maintaining a gross profit margin of 60.36% [2].

北京市中伦（深圳）律师事务所 关于深圳开立生物医疗科技股份有限公司 2025年第二次临时股东大会的 法律意见书 二〇二五年十二月 北京市中伦（深圳）律师事务所 关于深圳开立生物医疗科技股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：深圳开立生物医疗科技股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《上市公司股东 会规则》（以下简称"《股东会规则》"）和《深圳开立生物医疗科技股份有限公 司章程》（以下简称"《公司章程》"）的规定，北京市中伦（深圳）律师事务所 （以下简称"本所"）接受深圳开立生物医疗科技股份有限公司（以下简称公司"） 的委托，指派律师出席公司 2025 年第二次临时股东大会（以下简称"本次股东 大会"），并就本次股东大会的召集和召开程序、出席和列席会议人员资格、表决 程序及表决结果等事宜发表法律意见。 （一）本次股东大会的召集人 - 1 - 法律意见书 本次股东大会的召集人为公司董事会。本所律师认为，公司董事会具备召集 本次股东大会的资格。 （二）本次股东大会的通知 公 司 董 事 会 于 2025 年 12 月 12 日 在 信 息 披 露 指 定 网 ...

特此公告。 深圳开立生物医疗科技股份有限公司董事会 2025 年 12 月 30 日 证券代码：300633 证券简称：开立医疗 公告编号：2025-059 深圳开立生物医疗科技股份有限公司 关于选举职工代表董事的公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 深圳开立生物医疗科技股份有限公司（以下简称"公司"）于 2025 年 12 月 30 日召开 2025 年第二次临时股东大会，审议通过了《关于取消监事会、修订< 公司章程>并办理工商变更登记的议案》。根据修订后的《深圳开立生物医疗科技 股份有限公司章程》（以下简称"《公司章程》"）规定，公司设职工代表董事 1 名，由公司职工代表大会选举产生。 公司于 2025 年 12 月 30 日召开职工代表大会，经与会职工代表表决，选举 冯乃章先生（简历详见附件）为公司第四届董事会职工代表董事，任期自本次职 工代表大会选举通过之日起至第四届董事会任期届满之日止。冯乃章先生原为公 司第四届董事会非职工代表董事，本次选举完成后变更为第四届董事会职工代表 董事，公司第四届董事会成员及专门委员会成员构成不变。冯乃章先 ...

2、本次股东大会未涉及变更以往股东大会已通过的决议。 一、会议的召开和出席情况 （一）召开情况 1、召开时间： （1）现场会议：2025 年 12 月 30 日（星期二）下午 14:30 证券代码：300633 证券简称：开立医疗 公告编号：2025-058 深圳开立生物医疗科技股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏 特别提示： 1、本次股东大会未出现否决议案的情形； （2）网络投票：通过深圳证券交易所交易系统进行网络投票的时间为 2025 年 12 月 30 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深圳证券交易 所互联网系统投票的具体时间为 2025 年 12 月 30 日 9:15-15:00 期间的任意时间。 2、现场会议召开地点：深圳市光明区光电北路 368 号开立医疗大厦一楼 121 会议室 3、召开方式：现场表决与网络投票相结合的方式 4、召集人：深圳开立生物医疗科技股份有限公司董事会 5、主持人：董事长陈志强先生 6、会议的召开符合相关法律、行 ...